Stay updated with breaking news from Standard Poor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Exelixis positioned to expand its biotherapeutics development pipeline through selection of antibody candidates directed to targets identified using BioInvent's proprietary immuno-oncology (IO) screening
AXIS Insurance, the specialty insurance business segment of AXIS Capital Holdings Limited ("AXIS Capital") (NYSE: AXS), today announced it is combining its corporate accident and supplemental health
Regulatory News: SFL (Paris:FLY): NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, JAPAN, SOUTH AFRICA, AUSTRALIA OR IN ANY JURISDICTION
AXIS Capital Holdings Limited ("AXIS Capital") announced today a $250,000 endowment to INSEAD, the business school for the world, to create a research fund on behalf of former AXIS Chair of the Board
- Approval is based on COSMIC-311 trial, in which CABOMETYX demonstrated significant improvement in progression-free survival versus placebo - Exelixis, Inc. (Nasdaq: EXEL) today announced that